- Home
- JILL vs NERV Comparison
JILL vs NERV Comparison
Compare JILL & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JILL | NERV |
|---|---|---|
| Founded | 1959 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.1M | 207.7M |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | JILL | NERV |
|---|---|---|
| Price | $17.21 | $6.29 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $18.50 | $4.00 |
| AVG Volume (30 Days) | 41.5K | ★ 105.1K |
| Earning Date | 03-11-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.84% | N/A |
| EPS Growth | 3.98 | ★ 104.12 |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $610,857,000.00 | $41,175,600.00 |
| Revenue This Year | $0.10 | N/A |
| Revenue Next Year | $2.22 | N/A |
| P/E Ratio | $8.49 | ★ N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $13.32 | $1.15 |
| 52 Week High | $23.98 | $12.46 |
Technical Indicators
Market Signals| Indicator | JILL | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 62.10 | 67.25 |
| Support Level | $14.68 | $3.69 |
| Resistance Level | $17.56 | $6.69 |
| Average True Range (ATR) | 0.59 | 0.60 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 83.18 | 82.03 |
Price Performance
Historical ComparisonAbout JILL J. Jill Inc.
J.Jill Inc is a national lifestyle brand that provides apparel, footwear, and accessories. The company's products are marketed under the J.Jill brand name and sold through its two channels: its e-commerce platform and catalog (Direct) and its retail stores (Retail). Revenue is derived from the sale of apparel and accessory merchandise through the company's Retail and Direct channels, which include website and catalog phone orders. Revenue also includes shipping and handling fees collected from customers.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.